ICBB 2016 will be held in Budapest, Hungary on August 18 - 19, 2016.
Poster Board Dimensions:
Authors presenting via poster boards are to be informed that poster boards are 110 cm height and 70 cm width.
Best Paper Award:
Two best paper awards will be conferred to author(s) of the papers that receive the highest rank during the peer-review and by the respected session chairs. Please visit Paper Submission for more information.
Propose Exhibits, Workshops & More
ICBB attracts a wide range of researchers in the field of bioengineering and biotechnology. As a prominent company in the field of bioengineering and biotechnology, we would like to offer you an exhibit at ICBB. Please visit Events for more information.
We are very happy to announce the following keynote speakers for the 2nd International Conference on Bioengineering and Biotechnology (ICBB'16) will be announced soon. We appreciate your patience!
Dr. Imre Kacskovics
Dr. Kacskovics received his DVM degree in 1987, and his PhD (Characterization of the swine and bovine immunoglobulin genes) in 1998 from the University of Veterinary Science, Budapest. He spent his postdoctoral training at the University of Iowa from 1991 to 1994, and was a visiting scientist at the Karolinska Institute between 1995 and 2005. Since 2015, he has been a full professor and head at the Department of Immunology, Eötvös Loránd University, Budapest.
Dr. Kacskovics and his colleagues developed a new, innovative technology - IMG-AbSTM - in 2007. They created genetically modified mice and rabbits that overexpress the neonatal Fc receptor (FcRn). Because of the role of FcRn in antigen presentation, these animals have augmented humoral immune response and generate antibodies against weakly immunogenic antigens; produce highly diverse antibodies and higher number of antigen specific B cells; break immune tolerance to highly conserved antigens and significantly improve hybridoma production. Thus, FcRn transgenesis enjoys a number of practical benefits in research, diagnostics and therapy.
Dr. Kacskovics and his colleague founded a startup company, ImmunoGenes, to transfer this patented technology to business. In 2014, ImmunoGenes provided a non-exclusive license of its IMG-AbSTM technology to Kyowa Hakko Kirin, Japan (KHK). KHK is a global leader in the discovery and development of innovative therapeutic antibodies and has been using IMG-AbSTM technology to accelerate its antibody discovery efforts and increase its ability to generate therapeutic antibodies. ImmunoGenes have established collaborations with cutting-edge research groups (e.g. Institute of Experimental Medicine of the Hungarian Academy of Sciences; New York University, School of Medicine) to develop unique antibodies for research, diagnostics or therapy.
Topic of Keynote: Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptors as a result of augmented humoral immunityKeynote Abstract